8-K: Merck Reports Strong Q3, Raises 2025 EPS Outlook

Merck & Co., Inc. announced robust third-quarter 2025 financial results, driven by key product growth and pipeline advancements, leading to a raised full-year non-GAAP EPS forecast.

Summary

• Total worldwide sales for Q3 2025 reached $17.3 billion, a 4% increase (3% excluding foreign exchange) compared to Q3 2024.
• GAAP EPS was $2.32, an 87% increase, and non-GAAP EPS was $2.58, a 64% increase, both including a $0.10 per share charge for a milestone payment to LaNova.
• KEYTRUDA sales grew 10% to $8.1 billion, while WINREVAIR sales surged 141% to $360 million.
• CAPVAXIVE, launched in Q3 2024, generated $244 million in sales.
• GARDASIL/GARDASIL 9 sales declined 24% to $1.7 billion, primarily due to lower demand in China.
• Animal Health sales increased 9% to $1.6 billion.
• Received FDA approval for KEYTRUDA QLEX injection for subcutaneous use across all solid tumor indications.
• Announced positive topline results from the Phase 3 CORALreef Lipids trial for enlicitide decanoate, an investigational oral PCSK9 inhibitor.
• Completed the acquisition of Verona Pharma in October 2025, adding OHTUVAYRE for COPD maintenance treatment.
• Raised and narrowed the full-year 2025 non-GAAP EPS range to $8.93 to $8.98, and updated worldwide sales expectations to $64.5 billion to $65.0 billion.

Sentiment

Score: 8

Explanation: The filing presents a highly positive outlook with strong Q3 financial results, significant growth in key oncology and new products, successful pipeline advancements including regulatory approvals and positive trial data, and a raised full-year EPS guidance. Strategic investments in manufacturing and acquisitions further bolster long-term prospects, despite some declines in older products due to competition and regional demand shifts.

Positives

• Total worldwide sales increased 4% to $17.3 billion in Q3 2025, demonstrating strong top-line growth.
• GAAP EPS surged 87% to $2.32 and non-GAAP EPS increased 64% to $2.58, reflecting improved profitability.
• KEYTRUDA maintained strong growth, with sales up 10% to $8.1 billion, driven by demand in metastatic and earlier-stage indications.
• WINREVAIR sales showed exceptional growth of 141% to $360 million, indicating successful market uptake.
• CAPVAXIVE generated $244 million in sales, demonstrating continued uptake since its Q3 2024 launch.
• Animal Health segment grew 9% to $1.6 billion, with livestock products performing particularly well.
• FDA approval of KEYTRUDA QLEX (subcutaneous injection) expands treatment options and convenience for patients across all solid tumor indications.
• Positive topline results for enlicitide decanoate (oral PCSK9 inhibitor) in hypercholesterolemia trials suggest a significant pipeline asset.
• Acquisition of Verona Pharma and its COPD treatment OHTUVAYRE strengthens the cardio-pulmonary portfolio.
• Raised and narrowed the full-year 2025 non-GAAP EPS outlook to $8.93-$8.98, indicating increased confidence in future performance.
• Initiated a $3 billion investment for a new Center of Excellence for Pharmaceutical Manufacturing, signaling long-term growth commitment.

Negatives

• GARDASIL/GARDASIL 9 sales declined 24% to $1.7 billion, primarily due to lower demand in China.
• LAGEVRIO sales decreased significantly by 64% to $138 million due to lower demand in Asia Pacific and the U.S.
• SIMPONI sales declined 100% as marketing rights reverted to Johnson & Johnson on October 1, 2024.
• JANUVIA/JANUMET experienced lower demand in China and most other international markets due to generic competition, despite higher U.S. net pricing.
• VAXNEUVANCE sales declined 6% due to lower demand in certain international markets, particularly Japan, facing competitive pressure.
• Other Revenues declined 78% primarily due to unfavorable revenue-hedging activities and lower third-party manufacturing arrangements.

Risks

• General industry conditions and competition could impact market share and profitability.
• Fluctuations in interest rates and currency exchange rates may adversely affect financial results.
• Pharmaceutical industry regulation and health care legislation, both in the U.S. and internationally, could impose new costs or restrictions.
• Global trends toward health care cost containment may pressure pricing and reimbursement.
• Technological advances, new products, and patents attained by competitors could erode market position.
• Challenges inherent in new product development, including obtaining regulatory approval, may delay or prevent market entry.
• Inability to accurately predict future market conditions could lead to misallocation of resources.
• Manufacturing difficulties or delays could disrupt product supply and impact sales.
• Financial instability of international economies and sovereign risk may affect international operations and sales.
• Dependence on the effectiveness of patents and other protections for innovative products makes the company vulnerable to intellectual property challenges.
• Exposure to litigation, including patent litigation, and/or regulatory actions could result in significant financial penalties or operational disruptions.

Future Outlook

Merck now expects full-year 2025 worldwide sales to be between $64.5 billion and $65.0 billion, including a negative foreign exchange impact of approximately 0.5%. The company has raised and narrowed its full-year non-GAAP EPS outlook to be between $8.93 and $8.98, reflecting a net improvement of $0.04 per share at the midpoint compared to the prior outlook. This revised EPS outlook incorporates a $0.09 per share benefit from the Koselugo collaboration amendment, operational improvements, a more favorable estimated tax rate, and lower estimated costs related to tariffs, partially offset by a $0.04 per share negative impact from the Verona Pharma acquisition and incremental negative foreign exchange effects. The outlook includes one-time charges totaling $0.16 per share for the LaNova technology transfer and Hengrui Pharma license agreement.

Management Comments

• Robert M. Davis, chairman and chief executive officer, stated: 'In the third quarter, we continued to execute on our strategy with important pipeline advancements, significant approvals and successful new product launches.'
• Robert M. Davis also commented: 'We're delivering value to patients and customers through our innovative portfolio of medicines and vaccines, and we're securing our future by making important investments in our pipeline — including through compelling, strategic business development like our completed acquisition of Verona Pharma and expanded U.S. manufacturing and R&D spending.'
• Robert M. Davis added: 'With each milestone we achieve, my conviction that we're well-positioned to drive the next chapter of success for our Company increases.'

Industry Context

Merck's strong Q3 performance, particularly in oncology with KEYTRUDA and new product launches like WINREVAIR and CAPVAXIVE, positions it favorably within the highly competitive pharmaceutical industry. The strategic acquisition of Verona Pharma and its COPD treatment OHTUVAYRE, along with significant R&D and manufacturing investments, indicates a proactive approach to portfolio diversification and long-term growth. While some older products face generic competition and regional demand shifts (e.g., GARDASIL in China), the company's focus on innovative therapies and pipeline expansion aligns with broader industry trends emphasizing high-value, specialized treatments.

Comparison to Industry Standards

• The filing does not provide specific comparisons to comparable companies, projects, or global benchmarks within the industry. The analysis focuses on Merck's internal performance and pipeline advancements.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased EPS, raised outlook, and robust pipeline, potentially leading to increased share value.
• Patients: Positive impact through new drug approvals (KEYTRUDA QLEX, CAPVAXIVE in Japan) and promising pipeline candidates (enlicitide decanoate, OHTUVAYRE), offering new treatment options.
• Employees: Positive impact from significant investments in U.S. manufacturing and R&D, including the new $3 billion facility in Elkton, Virginia, which is expected to create over 500 full-time jobs.
• Customers (Healthcare Providers): Enhanced treatment options and convenience with new formulations like subcutaneous KEYTRUDA.
• Suppliers: Potential for increased demand for raw materials and services due to expanded manufacturing capabilities and R&D activities.

Next Steps

• A final decision on the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) positive opinion recommending approval for subcutaneous administration of KEYTRUDA is expected in the fourth quarter of 2025.
• Merck plans to present new data from its innovative cardiovascular pipeline and portfolio at the American Heart Association (AHA) Scientific Sessions 2025 from November 7-10.
• The company will host an Investor Event to coincide with the AHA Scientific Sessions 2025 on Sunday, November 9, in New Orleans.
• The FDA has set a Prescription Drug User Fee Act (PDUFA) date of April 7, 2026, for KEYTRUDA and KEYTRUDA QLEX in combination with Padcev for certain patients with MIBC.
• The FDA has set a PDUFA date of February 20, 2026, for KEYTRUDA plus chemotherapy for platinum-resistant recurrent ovarian cancer.

Key Dates

Recommendation

Merck's Q3 2025 results demonstrate exceptional financial health, with significant increases in sales and EPS, driven by strong performance of key growth drivers like KEYTRUDA and WINREVAIR. The raised full-year EPS outlook, coupled with strategic acquisitions (Verona Pharma) and substantial investments in manufacturing and R&D, signals robust long-term growth potential. The pipeline is delivering with multiple regulatory approvals and positive clinical trial readouts, particularly in oncology and cardiovascular disease. While some older products face headwinds, the overall momentum and strategic positioning make Merck a compelling 'strong buy' for investors seeking growth in the biopharmaceutical sector.

Keywords

Merck, MRK, Pharmaceuticals, Biotechnology, Oncology, KEYTRUDA, WINREVAIR, CAPVAXIVE, Vaccines, Animal Health, Q3 2025 Earnings, SEC Filing, 8-K, Drug Development, FDA Approval, Pipeline, Financial Results